1,344,510 Shares in Enanta Pharmaceuticals, Inc. $ENTA Bought by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management bought 1.34 million Enanta Pharmaceuticals shares worth approximately $19.6 million, giving it a 4.62% stake and making ENTA its 26th-largest holding.
• Analyst sentiment remains broadly positive, with six Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and a $19.50 average price target.
• Enanta’s latest quarterly results fell short of expectations: it reported a $0.67 per-share loss versus a projected $0.51 loss and revenue of $14.36 million versus the $16.76 million consensus estimate.

ADAR1 Capital Management LLC bought a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,344,510 shares of the biotechnology company's stock, valued at approximately $19,603,000. Enanta Pharmaceuticals makes up 0.9% of ADAR1 Capital Management LLC's investment portfolio, making the stock its 26th largest holding. ADAR1 Capital Management LLC owned about 4.62% of Enanta Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ENTA. Meeder Asset Management Inc. purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $32,000. Seven Fleet Capital Management LP purchased a new stake in Enanta Pharmaceuticals in the 4th quarter worth approximately $36,000. Legal & General Group Plc bought a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $41,000. Strs Ohio bought a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Enanta Pharmaceuticals by 333.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 2,758 shares during the period. Institutional investors own 94.99% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enanta Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.50.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $14.08 on Wednesday. Enanta Pharmaceuticals, Inc. has a 1 year low of $7.05 and a 1 year high of $17.15. The company has a 50 day simple moving average of $13.52 and a two-hundred day simple moving average of $13.47. The firm has a market cap of $410.08 million, a P/E ratio of -5.84 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The company had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. On average, sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.